Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance

References

• Alvarez RH, Guarneri V, Icli F, et al. (2011). Bevacizumab treatment for advanced breast cancer. Oncologist 16:1684–97
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633–40
   PubMedGoogle Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, et al. (2012). Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30:2585–92
   PubMed Web of Science ®Google Scholar
• Bottini A, Berruti A, Bersiga A, et al. (2000). p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6:2751–8
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Oliva C, et al. (2010). Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924–34
   PubMed Web of Science ®Google Scholar
• Chaisuparat R, Rojanawatsirivej S, Yodsanga S. (2012). Ribosomal protein S6 phosphorylation is associated with epithelial dysplasia and squamous cell carcinoma of the oral cavity. Pathol Oncol Res 19:189–93
   PubMed Web of Science ®Google Scholar
• Chaudhuri S, Lieberman I. (1968). Control of ribosome syntesis in normal and regenerating liver. J Biol Chem 243:29–33
   PubMed Web of Science ®Google Scholar
• Chung A, Cui X, Audeh W, Giuliano A. (2013). Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer 13:223–32
   PubMed Web of Science ®Google Scholar
• Ciruelos Gio EM. (2014). Targeting PI3K/AKT/mTOR pathway in estrogen receptor positive breast cancer. Cancer Treat Rev 40:862–71
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–48
   PubMed Web of Science ®Google Scholar
• Colby SR. (1967). Calculating synergistic and antagonistic responses of herbicide combinations. Weeds 15:20–2
   Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, Hern RA, et al. (2011). Assessment of Ki67 in Breast Cancer. Recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst 103:1656–64
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Luo J, et al. (2008). Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–8
   PubMed Web of Science ®Google Scholar
• Gianni L, Dafni U, Gelber RD, et al. (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 12:236–44
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Blumenschein GR Jr. (2012). Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39:313–20
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. (2009). High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700–6
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. (2009). High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumours 1 cm or smaller. J Clin Oncol 27:5700–6
   PubMed Web of Science ®Google Scholar
• Hagner PR, Schneider A, Gartenhaus RB. (2010). Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 18;115:2127–35
   Google Scholar
• Hayashi M, Okumura Y, Osako T, et al. (2012). Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. Front Oncol 2:62
   Google Scholar
• Holz MK. (2012). The role of S6K1 in ER-positive breast cancer. Cell Cycle 11:3159–65
   PubMed Web of Science ®Google Scholar
• Jalava P, Kuopio T, Juntti-Patinen L, et al. (2006). Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48:674–82
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Rorive A, Gollignon J. ( 2014). Use of mTOR inhibitors in the treatment of breast cancer: and evaluation of factors that influence patient outcomes. Breast Cancer 6:43–57
   PubMedGoogle Scholar
• Kümler I, Tuxen MK, Nielsen DL. (2013). A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 40:259–70
   PubMed Web of Science ®Google Scholar
• Khalaileh A, Dreazen A, Khatib A, et al. (2013). Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. Cancer Res 73:1811–20
   PubMed Web of Science ®Google Scholar
• Kontzoglou K, Palla V, Karaolanis G, et al. (2013). Correlation between Ki67 and breast cancer prognosis. Oncology 84:219–25
   PubMed Web of Science ®Google Scholar
• La Thangue NB, Kerr DJ. (2011). Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 23;8:587–96
   Google Scholar
• Lauring J, Park BH, Wolff AC. (2013). The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw 11:670–8
   PubMed Web of Science ®Google Scholar
• Lavaud P, Andre F. (2014). Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med 12:132
   PubMed Web of Science ®Google Scholar
• Mohd Sharial MS, Crown J, Hennessy BT. (2012). Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 23:3007–16
   PubMed Web of Science ®Google Scholar
• Molinolo AA, Hewitt SM, Amornphimoltham P, et al. (2007). Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13:4964–73
   PubMed Web of Science ®Google Scholar
• Nahta R. (2012). Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. Oncol 2012:428062
   Google Scholar
• Nahta R, O'Regan RM. (2010). Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer 10(Suppl. 3):S72–8
   PubMed Web of Science ®Google Scholar
• Nielsen PJ, Manchester KL, Towbin H, et al. (1982). The phosphorylation of ribosomal protein S6 in rat tissues following cycloheximide injection, in diabetes, and after denervation of diaphragm. A simple immunological determination of the extent of S6 phosphorylation on protein blots. J Biol Chem 257:12316–21
   PubMedGoogle Scholar
• Parker JL, Lushina N, Bal PS, et al. (2012). Impact of biomarkers on clinical trial risk in breast cancer. Breast Cancer Res Treat 136:179–85
   PubMed Web of Science ®Google Scholar
• Pernas S, Gil-Gil M, de Olza MO, et al. (2012). Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positivebreast cancer in everyday clinical practice. Breast Cancer Res Treat 134:1161–8
   PubMed Web of Science ®Google Scholar
• Rusnak D, Gilmer TM. (2011). The discovery of lapatinib (GW572016). Mol Cancer Ther 10:2019. doi: 10.1158/1535-7163.MCT-11-0697
   PubMed Web of Science ®Google Scholar
• Ruvinsky I, Sharon N, Lerer T, et al. (2005). Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19:2199–211
   PubMed Web of Science ®Google Scholar
• Sawaki M, Ito Y, Tada K, et al. (2004). Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumour 90:40–3
   PubMed Web of Science ®Google Scholar
• Sawyers CL. (2008). The cancer biomarker problem. Nature 452:548–52
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Chandarlapaty S, Prudkin L, et al. (2012). Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16:2688–95
   Web of Science ®Google Scholar
• Sendur MA, Aksoy S, Altundag K. (2013). Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 29:1015–24
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–82
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–12
   PubMed Web of Science ®Google Scholar
• Tan DS, Thomas GV, Garrett MD, et al. (2009). Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 15:406–20
   PubMed Web of Science ®Google Scholar
• Tripathy D. (2009). HER2 status and breast cancer therapy: recent advances. F1000 Med Rep 1:20. doi: 10.3410/M1-20
   Google Scholar
• Van Diest PJ, van der Wall E, Baak JP. (2004). Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57:675–81
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–26
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Hosoda M, Yamamoto M, et al. (2013). Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer 22:185–91
   PubMed Web of Science ®Google Scholar